Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.50 |
| ▸ | PPARA | Q07869 | 9/20 | 0.50 |
| ▸ | PPARD | Q03181 | 8/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.36 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.34 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455338 | 0.78 | PPARG (0.45) | PPARGPPARAPPARDPTPRZ1SMN1; SMN2 | |
| SCHEMBL4452067 | 0.74 | PPARG (0.43) | PPARGPPARAPPARDSMN1; SMN2MEN1 | |
| SCHEMBL14850364 | 0.71 | THRA (0.42) | PPARGPPARAPPARDPTPRZ1SMN1; SMN2 | |
| SCHEMBL4456825 | 0.71 | ALOX5 (0.43) | PPARGPPARAPPARDPTPRZ1SMN1; SMN2 | |
| SCHEMBL17354118 | 0.69 | PTPRZ1 (0.39) | PPARGPPARAPPARDPTPRZ1SMN1; SMN2 | |
| SCHEMBL8777238 | 0.68 | LTB4R (0.44) | PPARGPPARAPPARDPLA2G2DSMN1; SMN2 | |
| SCHEMBL13699 | 0.67 | SMN1; SMN2 (0.41) | PPARGPPARAPPARDPTPRZ1SMN1; SMN2 | |
| SCHEMBL8777252 | 0.67 | PPARD (0.43) | PPARGPPARAPPARDPLA2G2DSMN1; SMN2 | |
| SCHEMBL9821737 | 0.66 | PLA2G2D (0.42) | PPARGPPARAPPARDPLA2G2DSMN1; SMN2 | |
| SCHEMBL16479589 | 0.66 | PTPRZ1 (0.61) | PPARGPPARAPTPRZ1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524882-B2 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1539136-B1 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1539136-A4 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | disclosed |
| EP-1539136-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004010936-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO., INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.